Last updated: September 3, 2026
Abacavir sulfate/lamivudine is a mature fixed-dose HIV combination with limited branded revenue, broad generic availability, and no meaningful remaining U.S. market exclusivity. Its commercial decline reflects substitution by dolutegravir-based regimens, including Triumeq and Dovato, rather than loss of clinical utility. Financial value has shifted from the combination tablet itself to low-cost generic supply, public-sector procurement, and use of abacavir or lamivudine in selected treatment and pediatric settings.
What is abacavir sulfate/lamivudine and how is it used?
Abacavir sulfate/lamivudine combines two nucleoside reverse-transcriptase inhibitors in a once-daily tablet containing:
| Product attribute |
Detail |
| Active ingredients |
Abacavir sulfate 600 mg and lamivudine 300 mg |
| Original U.S. brand |
Epzicom |
| European and other markets |
Kivexa |
| Original developer |
GlaxoSmithKline |
| Current HIV commercial group |
ViiV Healthcare |
| FDA indication |
Combination antiretroviral treatment for HIV-1 infection |
| FDA approval |
August 2004 |
| Dosing |
One tablet daily, used with other antiretroviral agents |
| Key safety restriction |
HLA-B*5701 testing before abacavir use |
| Major clinical limitation |
Abacavir is generally avoided in patients with a high cardiovascular-risk profile when alternatives are suitable |
The tablet is not a complete HIV regimen. It is a two-drug nucleoside backbone and must be paired with an additional active antiretroviral, historically including efavirenz, boosted protease inhibitors, or an integrase inhibitor. The FDA labeling requires HLA-B*5701 screening because abacavir hypersensitivity can be severe or fatal in genetically susceptible patients (U.S. Food and Drug Administration [FDA], 2023).
When does abacavir sulfate/lamivudine lose exclusivity?
U.S. exclusivity for the fixed-dose combination has expired, and generic products are available. The original product also faced separate loss of exclusivity for its two active ingredients.
| Exclusivity element |
Commercial effect |
| Abacavir compound protection |
Expired |
| Lamivudine compound protection |
Expired |
| Epzicom fixed-dose product protection |
Expired |
| FDA small-molecule exclusivity |
Expired |
| Generic entry |
Established |
| Current branded barrier |
Primarily clinical preference, contracting, and supply reliability |
The relevant patent estate was built around the individual active ingredients, their salts, combinations, and manufacturing processes. Those rights were filed principally in the 1980s and 1990s. Their ordinary patent terms have elapsed in the United States and major European markets. Any pediatric extensions or regulatory exclusivities associated with earlier approvals no longer create a meaningful commercial barrier.
What patents protect abacavir sulfate and lamivudine?
The historical patent estate included compound patents, salt forms, pharmaceutical compositions, combination claims, and manufacturing processes. The commercially important compound rights have expired.
Abacavir patent position
Abacavir was originally developed by Glaxo Wellcome and commercialized as Ziagen. The historical U.S. compound patent estate included U.S. Patent No. 5,034,394, which covered abacavir-related chemical matter. That protection expired before the current market period.
Later rights covered formulations, combinations, and manufacturing processes. These patents did not preserve a durable branded monopoly for the abacavir/lamivudine tablet after generic entry.
Lamivudine patent position
Lamivudine was also developed within the Glaxo group and commercialized as Epivir. Historical composition and compound patents included U.S. Patent No. 5,047,407. Those rights expired, allowing broad generic competition in lamivudine monotherapy and combination products.
Combination-product protection
The fixed-dose product had additional formulation and combination filings. Those rights were directed to combining abacavir and lamivudine in a pharmaceutical dosage form and did not prevent later generic approval once the relevant U.S. patent and exclusivity barriers ended.
What is the Orange Book status of Epzicom?
Epzicom was approved under NDA 021652. The FDA Orange Book historically listed patents associated with the product, but the commercially relevant listings are expired. Generic abacavir sulfate/lamivudine tablets have therefore been eligible for approval through the abbreviated new drug application pathway.
The product is no longer protected by a live U.S. Orange Book patent that supports a meaningful launch-blocking strategy. Any Paragraph IV activity would be commercially limited because the core branded market has already undergone generic erosion.
Which companies are challenging abacavir sulfate/lamivudine?
Competition comes primarily from generic manufacturers rather than a concentrated litigation campaign. U.S. generic suppliers have included companies such as Mylan, Teva, and other approved ANDA holders, depending on the relevant product presentation and distribution period.
The competitive structure differs from a current high-value branded product:
- Multiple suppliers can compete for pharmacy and institutional contracts.
- Abacavir/lamivudine is generally dispensed as a low-cost generic.
- Supply interruptions and tender awards can matter more than patent disputes.
- Manufacturers compete on API sourcing, quality compliance, inventory, and government procurement access.
No biosimilar pathway applies because abacavir sulfate/lamivudine is a chemically synthesized small-molecule product. The relevant regulatory route is an ANDA, not a biosimilar application under the Public Health Service Act.
What generic entry risks exist for Epzicom?
Generic entry risk is no longer a future event. It is the current market structure.
The branded product faces four forms of erosion:
- Generic substitution at the pharmacy level.
- Formulary exclusion or unfavorable reimbursement.
- Physician migration to newer integrase-inhibitor regimens.
- Price compression in public-sector and tender markets.
A branded relaunch would not have a credible U.S. premium-price thesis unless supported by a new delivery technology, a differentiated patient population, or a supply-chain advantage. The original tablet has no remaining patent-based ability to sustain premium pricing.
How does abacavir sulfate/lamivudine compare with Triumeq and Dovato?
The fixed-dose combination is commercially weaker than the newer ViiV products that use the same or related components.
| Product |
Composition |
Strategic position |
| Epzicom/Kivexa |
Abacavir plus lamivudine |
Two-drug NRTI backbone requiring a third agent |
| Triumeq |
Abacavir, dolutegravir, and lamivudine |
Complete three-drug, once-daily regimen |
| Dovato |
Dolutegravir and lamivudine |
Complete two-drug regimen |
| Generic abacavir/lamivudine |
Abacavir plus lamivudine |
Low-cost backbone for selected regimens |
| Biktarvy |
Bictegravir, emtricitabine, and tenofovir alafenamide |
Major competing complete regimen from Gilead |
Triumeq improved the commercial utility of abacavir/lamivudine by adding dolutegravir. Dovato reduced demand for the two-NRTI backbone because it uses lamivudine with dolutegravir and excludes abacavir. Biktarvy and other tenofovir-based integrase regimens have captured much of the treatment market because of strong efficacy, single-tablet convenience, and broader prescribing preference.
Abacavir remains clinically relevant when renal considerations favor avoiding tenofovir, when a patient is already stable on an abacavir-containing regimen, or when cost and local formulary access drive selection. HLA-B*5701 screening and cardiovascular-risk concerns limit expansion.
What is the FDA regulatory status of abacavir sulfate/lamivudine?
FDA status is mature and genericized:
- Epzicom is an approved fixed-dose combination.
- Generic abacavir sulfate/lamivudine tablets are approved through ANDAs.
- The drug is not a biologic and has no biosimilar competition.
- No new chemical-entity exclusivity remains.
- HLA-B*5701 testing remains a central labeling requirement.
- The FDA-approved strength is 600 mg abacavir and 300 mg lamivudine per tablet.
Lamivudine also has broad use in hepatitis B treatment at different dosing and product configurations. That market is separate from HIV combination demand and should not be counted as revenue for abacavir/lamivudine.
What is the financial trajectory for abacavir sulfate/lamivudine?
The financial trajectory is a long-term decline in branded value followed by a stable, low-margin generic phase.
Brand revenue trajectory
ViiV Healthcare and its parent companies do not generally disclose Epzicom or Kivexa as standalone revenue lines. Financial reporting emphasizes larger HIV brands, including Tivicay, Triumeq, Dovato, and long-acting Cabenuva. This prevents a precise public revenue series for abacavir/lamivudine alone.
The commercial sequence is clear:
| Period |
Financial condition |
| 2004 to late 2000s |
Branded growth as a once-daily NRTI backbone |
| Early to mid-2010s |
Decline as integrase-inhibitor and single-tablet regimens expanded |
| After generic entry |
Rapid price and volume pressure |
| Current market |
Low-value branded product, established generic demand |
| Forward outlook |
Stable unit demand in selected markets, declining branded economics |
Triumeq temporarily supported demand for abacavir and lamivudine, but that value accrued to the complete three-drug product rather than the Epzicom tablet. As Triumeq matures and patients move to newer regimens, the financial contribution of abacavir-containing products faces further pressure.
Generic financial model
Generic profitability depends on:
- Active pharmaceutical ingredient cost;
- Regulatory compliance and manufacturing scale;
- Government tender participation;
- Pharmacy benefit manager reimbursement;
- Number of approved suppliers;
- Product availability and back-order frequency.
Margins are generally thin because the product is therapeutically substitutable and has several potential suppliers. Manufacturing economics can improve where a company has vertically integrated API production or a reliable low-cost supply base. The largest risk is not patent infringement but quality failure, supply interruption, or loss of a high-volume tender.
What licensing deals affect the market?
The product originated from the Glaxo/Glaxo Wellcome research and commercial organization and is now associated with ViiV Healthcare, the HIV-focused company owned by GSK, Pfizer, and Shionogi. The major strategic licensing and corporate transaction relevant to the product is the formation and ownership structure of ViiV.
No current licensing arrangement is known to create a new exclusivity layer for the abacavir/lamivudine fixed-dose tablet. Generic supply agreements and public-health licensing arrangements may affect regional access, but they do not restore U.S. patent protection.
What patent litigation affects abacavir sulfate/lamivudine?
The product is not a current high-value patent-litigation target. Its principal U.S. patent disputes occurred during the period before or around genericization, when branded sales could justify ANDA litigation. The present commercial environment is characterized by expired core rights, approved generic products, and low expected damages.
Settlement agreements, if any, are unlikely to have a material effect on current U.S. market structure. A litigation strategy based on the original compound or combination claims would face expiration and invalidity timing problems.
What geographic markets still matter?
The highest remaining commercial relevance is outside the premium U.S. branded market.
United States
The U.S. market is genericized. Abacavir/lamivudine remains available for clinical use but has limited branded pricing power.
Europe
Kivexa has faced the same structural pressures as Epzicom. National reimbursement systems and tendering accelerate generic substitution. Market access depends on country-level pricing and procurement decisions.
Low- and middle-income countries
Abacavir and lamivudine remain relevant where treatment guidelines, pediatric formulations, renal considerations, or procurement economics support use. In these markets, commercial value is measured by volume and tender access rather than high per-patient pricing.
How strong is the patent estate for abacavir sulfate/lamivudine?
The current patent estate is weak for exclusivity purposes.
| Factor |
Assessment |
| Core compound patents |
Expired |
| Fixed-dose combination patents |
Expired or commercially non-blocking |
| Orange Book leverage |
Limited |
| Paragraph IV exposure |
Low strategic significance |
| Biosimilar risk |
Not applicable |
| Manufacturing barriers |
Moderate only where API or quality controls are difficult |
| Regulatory barrier |
Low for approved generic suppliers |
| Brand pricing power |
Low |
| Clinical differentiation |
Narrow and patient-specific |
The remaining defensibility is operational rather than legal. A manufacturer with dependable supply, competitive cost, pediatric capability, or strong government-contract execution can retain share without owning enforceable patents.
Key Takeaways
- Abacavir sulfate/lamivudine is an FDA-approved, mature HIV fixed-dose combination marketed originally as Epzicom and Kivexa.
- Core compound and combination patent protection has expired.
- Generic entry is established, and current U.S. competition is based on price, supply, and contracting.
- No biosimilar risk applies because the product is a small-molecule drug.
- Demand has shifted toward dolutegravir-based products, including Triumeq and Dovato, and toward tenofovir-based single-tablet regimens.
- ViiV does not publicly report Epzicom or Kivexa as standalone revenue lines, preventing a precise product-level revenue forecast.
- Branded financial value is low and declining; generic demand is likely to remain stable in selected clinical and procurement channels.
- The main commercial barriers are manufacturing reliability, API economics, quality compliance, and tender access, not live patent rights.
FAQs
Is abacavir sulfate/lamivudine still commercially available?
Yes. The combination remains available as Epzicom or Kivexa in certain markets and through generic tablets, although prescribing has shifted toward newer complete regimens.
Does abacavir/lamivudine require HLA-B*5701 testing?
Yes. Patients should be tested for HLA-B*5701 before starting abacavir-containing treatment, consistent with FDA labeling.
Can generic abacavir/lamivudine be launched through an ANDA?
Yes. The product is a small-molecule fixed-dose combination with expired core exclusivity, making the ANDA pathway the relevant U.S. regulatory route.
Is abacavir/lamivudine protected by patents in Europe?
The original compound and product patent protections have expired in major European markets. National regulatory, pricing, and procurement rules still affect market access.
Is abacavir/lamivudine a high-growth pharmaceutical market?
No. It is a mature, low-growth market. The most likely trajectory is stable generic volume in selected segments and continued decline in branded revenue.
References
-
GlaxoSmithKline. (2004). Epzicom: Abacavir sulfate and lamivudine prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2023). Epzicom (abacavir sulfate and lamivudine) prescribing information. https://www.accessdata.fda.gov
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
ViiV Healthcare. (2024). ViiV Healthcare annual and financial information. https://viivhealthcare.com
-
GSK plc. (2024). Annual report 2023. https://www.gsk.com/en-gb/investors/financial-results/
-
World Health Organization. (2023). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. https://www.who.int/publications/i/item/9789240031593
-
United States Patent and Trademark Office. (1989). U.S. Patent No. 5,034,394: Carbocyclic nucleosides.
-
United States Patent and Trademark Office. (1991). U.S. Patent No. 5,047,407: Enantiomeric nucleoside analogues.
